A new trading day began on Thursday, with CRISPR Therapeutics AG (NASDAQ: CRSP) stock price down -0.03% from the previous day of trading, before settling in for the closing price of $37.78. CRSP’s price has ranged from $30.04 to $67.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 31550.17% over the past five years. Meanwhile, its annual earnings per share averaged -11.69%. With a float of $82.46 million, this company’s outstanding shares have now reached $85.74 million.
Let’s look at the performance matrix of the company that is accounted for 393 employees. In terms of profitability, gross margin is -227.47%, operating margin of -1273.97%, and the pretax margin is -990.27%.
CRISPR Therapeutics AG (CRSP) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of CRISPR Therapeutics AG is 4.33%, while institutional ownership is 69.09%. The most recent insider transaction that took place on Mar 21 ’25, was worth 413,578. In this transaction Chief Executive Officer of this company sold 10,031 shares at a rate of $41.23, taking the stock ownership to the 195,085 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Operating Officer sold 1,714 for $41.23, making the entire transaction worth $70,668. This insider now owns 10,544 shares in total.
CRISPR Therapeutics AG (CRSP) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.26 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -11.69% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Here are CRISPR Therapeutics AG’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 22.07. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 87.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.36, a number that is poised to hit -1.22 in the next quarter and is forecasted to reach -3.99 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics AG (NASDAQ: CRSP) saw its 5-day average volume 2.23 million, a positive change from its year-to-date volume of 2.23 million. As of the previous 9 days, the stock’s Stochastic %D was 80.55%. Additionally, its Average True Range was 2.54.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 29.91%, which indicates a significant decrease from 76.62% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.24% in the past 14 days, which was higher than the 63.08% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $41.04, while its 200-day Moving Average is $46.09. Nevertheless, the first resistance level for the watch stands at $38.25 in the near term. At $38.72, the stock is likely to face the second major resistance level. The third major resistance level sits at $39.23. If the price goes on to break the first support level at $37.26, it is likely to go to the next support level at $36.75. Assuming the price breaks the second support level, the third support level stands at $36.28.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
With a market capitalization of 3.26 billion, the company has a total of 85,774K Shares Outstanding. Currently, annual sales are 37,310 K while annual income is -366,250 K. The company’s previous quarter sales were 35,690 K while its latest quarter income was -37,310 K.
